Please login to the form below

Not currently logged in
Email:
Password:

neurodegeneration

This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.

Theranexus takes Alzheimer’s drug combo into clinic

Theranexus takes Alzheimer’s drug combo into clinic

While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid

Latest news

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination… it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious

  • Pharma deals in September 2015 Pharma deals in September 2015

    Gencia is also at the discovery phase in mitochondrial therapies in neurodegeneration, cardiovascular disease and other areas.

  • Pharma deals during February 2014 Pharma deals during February 2014

    adolescence, and ultimately neurodegeneration due to the formation of fatty yellow nodules (xanthomas) in the brain.

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    influence driving the neurodegeneration seen in the disease. ... of molecules throughout the cell – leading to neurodegeneration. “

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics